MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2025018894

Медицинская библиотека · Blood advances · 2026

Deferasirox 6 months after allo-HSCT in AML/MDS: a prospective propensity-matched study.

Buono Romain, Huynh Anne, Forcade Edouard, Labussière Hélène, Ceballos Patrice, Cornillon Jérôme, Cabrera Quentin, D'Aveni Maud, Robin Marie, Devillier Raynier, Raus Nicole, Michallet Mauricette

СтатьяНаблюдательное исследованиеМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

Iron overload after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with oxidative stress and adverse outcomes. Although deferasirox reduces ferritin, its effect on survival remains incompletely characterized. We conducted a prospective observational study across 7 French centers, enrolling 41 patients with acute myeloid leukemia or myelodysplastic syndromes who initiated deferasirox 6 months after allo-HSCT. Eligibility required complete remission, iron overload (ferritin level >1000 μg/L), and preserved organ function. Outcomes were compared with propensity score-matched controls (1:2) from the SFGM-TC registry. End points were overall survival (OS), progression-free survival (PFS), transplant-related mortality (TRM), relapse, and safety. Analyses employed exact matching, inverse probability of treatment weighting (IPTW), and multivariable Cox models. Ferritin level decreased from 1700 μg/L to <1000 μg/L by 18 months. Across analytic methods, deferasirox was associated with a reduced hazard of progression or death (PFS: hazard ratio [HR], 0.41-0.44) and a reduced hazard of mortality (OS: HR, 0.28-0.43). TRM was significantly reduced in propensity score matching and Cox models (HR, 0.21), whereas the IPTW analysis yielded a comparable point estimate (HR, 0.24) that did not reach the significance threshold (P = .063). The probability of relapse (estimated via cumulative incidence of relapse) did not differ significantly. Adverse events were predominantly renal and manageable. Initiating deferasirox 6 months after allo-HSCT was associated with sustained ferritin reduction, a reduced hazard of progression or death (PFS), lower TRM, and a favorable although nonsignificant hazard of mortality (OS), with acceptable safety. These findings support deferasirox as a feasible posttransplant intervention, warranting confirmation in randomized trials.

Для цитирования: Buono Romain, Huynh Anne, Forcade Edouard, Labussière Hélène, Ceballos Patrice, Cornillon Jérôme, Cabrera Quentin, D'Aveni Maud, Robin Marie, Devillier Raynier, Raus Nicole, Michallet Mauricette. Deferasirox 6 months after allo-HSCT in AML/MDS: a prospective propensity-matched study.. Blood advances. 2026. DOI: 10.1182/bloodadvances.2025018894.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.